Overcoming biological barriers by virus-like drug particles for drug delivery

Chen, Yu-Ling; Bao, Chun-Jie; Duan, Jia-Lun; Xie, Ying; Lu, Wan-Liang

doi:10.1016/j.addr.2023.115134

Cited by 10 publications

(4 citation statements)

References 280 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Nanoparticle-based Combination Strategies For Overcoming The...mentioning

confidence: 99%

“… 169 , 170 Understanding individual patient profiles could lead to the development of custom-tailored nanoparticle systems, optimizing treatment efficacy while minimizing side effects. 159 Ethical considerations and conflicts of interest are essential in research involving human participants. This includes ensuring informed consent through informed consent forms that detail the scope and potential risks of the study.…”

Section: Conclusion and Future Perspectivementioning

confidence: 99%

“…158 Research on brain tumor treatment using VLPs is still in its early stages, but it holds promise as various viruses capable of crossing the BBB have been reported, suggesting a potential avenue for exploration. 159 The safety and biocompatibility of VLPs are paramount for their use in clinical applications. Despite the potential of VLPs in GBM treatment, challenges remain in translating these technologies from the laboratory to the clinic.…”

Section: Intranasal Np Drug Deliverymentioning

confidence: 99%

“…Research has shown that virus and bacteria can cross the BBB through transcellular, paracellular, or Trojan horse mechanisms. 159 To advance the development and clinical translation of bacterial nanoparticle-based therapies for glioblastoma, it is essential to resolve challenges related to immunogenicity, scalability, target specificity and microbiome interactions. 161 However, successful clinical application of combination therapy requires careful consideration and optimization of several factors.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Nanoparticle-Based Combinational Strategies for Overcoming the Blood-Brain Barrier and Blood-Tumor Barrier

Lim,

Yee,

Khang

2024

IJN

View full text Add to dashboard Cite

The blood-brain barrier (BBB) and blood-tumor barrier (BTB) pose substantial challenges to efficacious drug delivery for glioblastoma multiforme (GBM), a primary brain tumor with poor prognosis. Nanoparticle-based combinational strategies have emerged as promising modalities to overcome these barriers and enhance drug penetration into the brain parenchyma. This review discusses various nanoparticle-based combinatorial approaches that combine nanoparticles with cell-based drug delivery, viral drug delivery, focused ultrasound, magnetic field, and intranasal drug delivery to enhance drug permeability across the BBB and BTB. Cell-based drug delivery involves using engineered cells as carriers for nanoparticles, taking advantage of their intrinsic migratory and homing capabilities to facilitate the transport of therapeutic payloads across BBB and BTB. Viral drug delivery uses engineered viral vectors to deliver therapeutic genes or payloads to specific cells within the GBM microenvironment. Focused ultrasound, coupled with microbubbles or nanoparticles, can temporarily disrupt the BBB to increase drug permeability. Magnetic field-guided drug delivery exploits magnetic nanoparticles to facilitate targeted drug delivery under an external magnetic field. Intranasal drug delivery offers a minimally invasive avenue to bypass the BBB and deliver therapeutic agents directly to the brain via olfactory and trigeminal pathways. By combining these strategies, synergistic effects can enhance drug delivery efficiency, improve therapeutic efficacy, and reduce off-target effects. Future research should focus on optimizing nanoparticle design, exploring new combination strategies, and advancing preclinical and clinical investigations to promote the translation of nanoparticle-based combination therapies for GBM.

show abstract

Section: Nanoparticle-based Combination Strategies For Overcoming The...mentioning

confidence: 99%

Section: Conclusion and Future Perspectivementioning

confidence: 99%

Section: Intranasal Np Drug Deliverymentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Nanoparticle-Based Combinational Strategies for Overcoming the Blood-Brain Barrier and Blood-Tumor Barrier

Lim,

Yee,

Khang

2024

IJN

View full text Add to dashboard Cite

show abstract

Porous egg microparticles for controllable drug delivery and oncotherapy

Yan,

Wang,

Xie

2024

Precision Medical Sciences

View full text Add to dashboard Cite

Baicalein (BAI) extracted from Chinese herb has been proved to increase the sensitivity of tumor cells to gemcitabine (GEM) and effectively solve the problem of drug resistance of tumor cells. Nevertheless, intravenous administration often leads to intolerance of patients and side effects. In this paper, we introduced egg‐based porous microparticles for controllable drug delivery and oncotherapy, which avoided frequent intravenous administration. The interconnected porous structure endowed the microparticles with the capacity of loading sufficient drugs and releasing in a controllable way by adjusting the concentration and proportion of egg white and yolk. We have demonstrated that the cell viability of drug delivery system group was less than 50%, while the single drug group was more than 70%, which indicated that the co‐delivery of GEM and BAI could significantly reduce the proliferation of cells. These features indicated that the egg porous microparticles are ideal for controllable drug delivery and oncotherapy.

show abstract

Cancer Nanovaccines: Nanomaterials and Clinical Perspectives

Desai,

Chavda,

Singh

et al. 2024

Small

View full text Add to dashboard Cite

Cancer nanovaccines represent a promising frontier in cancer immunotherapy, utilizing nanotechnology to augment traditional vaccine efficacy. This review comprehensively examines the current state‐of‐the‐art in cancer nanovaccine development, elucidating innovative strategies and technologies employed in their design. It explores both preclinical and clinical advancements, emphasizing key studies demonstrating their potential to elicit robust anti‐tumor immune responses. The study encompasses various facets, including integrating biomaterial‐based nanocarriers for antigen delivery, adjuvant selection, and the impact of nanoscale properties on vaccine performance. Detailed insights into the complex interplay between the tumor microenvironment and nanovaccine responses are provided, highlighting challenges and opportunities in optimizing therapeutic outcomes. Additionally, the study presents a thorough analysis of ongoing clinical trials, presenting a snapshot of the current clinical landscape. By curating the latest scientific findings and clinical developments, this study aims to serve as a comprehensive resource for researchers and clinicians engaged in advancing cancer immunotherapy. Integrating nanotechnology into vaccine design holds immense promise for revolutionizing cancer treatment paradigms, and this review provides a timely update on the evolving landscape of cancer nanovaccines.

show abstract

Overcoming biological barriers by virus-like drug particles for drug delivery

Cited by 10 publications

References 280 publications

Nanoparticle-Based Combinational Strategies for Overcoming the Blood-Brain Barrier and Blood-Tumor Barrier

Nanoparticle-Based Combinational Strategies for Overcoming the Blood-Brain Barrier and Blood-Tumor Barrier

Porous egg microparticles for controllable drug delivery and oncotherapy

Cancer Nanovaccines: Nanomaterials and Clinical Perspectives

Contact Info

Product

Resources

About